These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 31395668)

  • 1. Imaging biomarkers for malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
    Ahlawat S; Blakeley JO; Rodriguez FJ; Fayad LM
    Neurology; 2019 Sep; 93(11):e1076-e1084. PubMed ID: 31395668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of intratumoural heterogeneity on ¹⁸F-FDG PET/CT for characterization of peripheral nerve sheath tumours in neurofibromatosis type 1.
    Salamon J; Derlin T; Bannas P; Busch JD; Herrmann J; Bockhorn M; Hagel C; Friedrich RE; Adam G; Mautner VF
    Eur J Nucl Med Mol Imaging; 2013 May; 40(5):685-92. PubMed ID: 23232507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiparametric whole-body anatomic, functional, and metabolic imaging characteristics of peripheral lesions in patients with schwannomatosis.
    Ahlawat S; Baig A; Blakeley JO; Jacobs MA; Fayad LM
    J Magn Reson Imaging; 2016 Oct; 44(4):794-803. PubMed ID: 26991037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging cellularity in benign and malignant peripheral nerve sheath tumors: Utility of the "target sign" by diffusion weighted imaging.
    Ahlawat S; Fayad LM
    Eur J Radiol; 2018 May; 102():195-201. PubMed ID: 29685535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral nerve sheath tumor: differentiation of malignant from benign tumors with conventional and diffusion-weighted MRI.
    Yun JS; Lee MH; Lee SM; Lee JS; Kim HJ; Lee SJ; Chung HW; Lee SH; Shin MJ
    Eur Radiol; 2021 Mar; 31(3):1548-1557. PubMed ID: 32894357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
    Derlin T; Tornquist K; Münster S; Apostolova I; Hagel C; Friedrich RE; Wedegärtner U; Mautner VF
    Clin Nucl Med; 2013 Jan; 38(1):e19-25. PubMed ID: 23242059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-FDG PET/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: comparison of early to delayed imaging with and without liver activity normalization.
    Chirindel A; Chaudhry M; Blakeley JO; Wahl R
    J Nucl Med; 2015 Mar; 56(3):379-85. PubMed ID: 25655626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiation of peripheral nerve sheath tumors in patients with neurofibromatosis type 1 using diffusion-weighted magnetic resonance imaging.
    Well L; Salamon J; Kaul MG; Farschtschi S; Herrmann J; Geier KI; Hagel C; Bockhorn M; Bannas P; Adam G; Mautner VF; Derlin T
    Neuro Oncol; 2019 Mar; 21(4):508-516. PubMed ID: 30496452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI.
    Reinert CP; Schuhmann MU; Bender B; Gugel I; la Fougère C; Schäfer J; Gatidis S
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):776-787. PubMed ID: 30535768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nerve Sheath Tumors in Neurofibromatosis Type 1: Assessment of Whole-Body Metabolic Tumor Burden Using F-18-FDG PET/CT.
    Salamon J; Papp L; Tóth Z; Laqmani A; Apostolova I; Adam G; Mautner VF; Derlin T
    PLoS One; 2015; 10(12):e0143305. PubMed ID: 26625155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asymmetry of thalamic hypometabolism on FDG-PET/CT in neurofibromatosis type 1: Association with peripheral tumor burden.
    Özden C; Mautner VF; Farschtschi S; Molwitz I; Ristow I; Bannas P; Well L; Klutmann S; Adam G; Apostolova I; Buchert R
    J Neuroimaging; 2024; 34(1):138-144. PubMed ID: 37942683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: tumour-to-liver ratio is superior to an SUVmax cut-off.
    Salamon J; Veldhoen S; Apostolova I; Bannas P; Yamamura J; Herrmann J; Friedrich RE; Adam G; Mautner VF; Derlin T
    Eur Radiol; 2014 Feb; 24(2):405-12. PubMed ID: 24097302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study.
    Ferner RE; Golding JF; Smith M; Calonje E; Jan W; Sanjayanathan V; O'Doherty M
    Ann Oncol; 2008 Feb; 19(2):390-4. PubMed ID: 17932395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous whole body (18)F-fluorodeoxyglucose positron emission tomography magnetic resonance imaging for evaluation of pediatric cancer: Preliminary experience and comparison with (18)F-fluorodeoxyglucose positron emission tomography computed tomography.
    Pugmire BS; Guimaraes AR; Lim R; Friedmann AM; Huang M; Ebb D; Weinstein H; Catalano OA; Mahmood U; Catana C; Gee MS
    World J Radiol; 2016 Mar; 8(3):322-30. PubMed ID: 27028112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anatomic and metabolic evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis 1 using whole-body MRI and (18)F-FDG PET fusion.
    Urban T; Lim R; Merker VL; Muzikansky A; Harris GJ; Kassarjian A; Bredella MA; Plotkin SR
    Clin Nucl Med; 2014 May; 39(5):e301-7. PubMed ID: 24152623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of (18)F-FDG PET and MRI in differentiating benign and malignant peripheral nerve sheath tumors.
    Broski SM; Johnson GB; Howe BM; Nathan MA; Wenger DE; Spinner RJ; Amrami KK
    Skeletal Radiol; 2016 Aug; 45(8):1097-105. PubMed ID: 27115884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential role of 18fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1.
    Karabatsou K; Kiehl TR; Wilson DM; Hendler A; Guha A
    Neurosurgery; 2009 Oct; 65(4 Suppl):A160-70. PubMed ID: 19927062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign.
    Benz MR; Czernin J; Dry SM; Tap WD; Allen-Auerbach MS; Elashoff D; Phelps ME; Weber WA; Eilber FC
    Cancer; 2010 Jan; 116(2):451-8. PubMed ID: 19924789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conventional and functional MR imaging of peripheral nerve sheath tumors: initial experience.
    Demehri S; Belzberg A; Blakeley J; Fayad LM
    AJNR Am J Neuroradiol; 2014 Aug; 35(8):1615-20. PubMed ID: 24763412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diffusion-Weighted Magnetic Resonance Imaging Improves the Accuracy of Differentiation of Benign from Malignant Peripheral Nerve Sheath Tumors.
    Koike H; Nishida Y; Ito S; Shimoyama Y; Ikuta K; Urakawa H; Sakai T; Shimizu K; Ito K; Imagama S
    World Neurosurg; 2022 Jan; 157():e207-e214. PubMed ID: 34624521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.